Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611486 | 0.85 | GLA (0.62) | SMN1; SMN2LMNAALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL18171802 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNAALDH1A1KDM4ETSHR | |
| SCHEMBL5324208 | 0.82 | ALDH1A1 (0.67) | SMN1; SMN2LMNAALDH1A1KDM4ETSHR | |
| SCHEMBL10487900 | 0.82 | MEN1 (0.72) | LMNAALDH1A1MAPTKDM4EHDAC8 | |
| SCHEMBL5320439 | 0.80 | ALDH1A1 (0.58) | SMN1; SMN2LMNAALDH1A1TSHRL3MBTL1 | |
| SCHEMBL18180338 | 0.79 | APEX1 (0.73) | ALDH1A1MAPTKDM4EL3MBTL1MEN1 | |
| SCHEMBL7439033 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL10487883 | 0.76 | HDAC1 (0.64) | ALDH1A1MAPTKDM4EHDAC8HDAC6 | |
| SCHEMBL10487902 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL13332552 | 0.75 | MAPT (0.61) | SMN1; SMN2ALDH1A1MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| EP-3286174-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172425-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | SMN1; SMN2 2518/4885LMNA 3382/4885ALDH1A1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.